Low‐energy differential target multiplexed SCS derivative reduces pain and improves quality of life through 12 months in patients with chronic back and/or leg pain.
Introduction: Energy‐reducing spinal cord stimulation (SCS) approaches have the potential to impact patient experience with rechargeable and non‐rechargeable SCS devices through reducing device recharge time or enhancing device longevity. This prospective, multi‐center study evaluated the safety, ef...
| Publicado en: | Pain Practice Vol. 25; no. 1; pp. 1 - 14 |
|---|---|
| Autores principales: | , , , , , , , , , , , , , , , , , , , |
| Formato: | clinical trial research tables/charts Journal Article |
| Publicado: |
Wiley-Blackwell
Jan2025
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=183925938&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 183925938 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 15307085 HYN jtl: Pain Practice issn: 15307085 maglogo: Y pubinfo: dt: Jan2025 vid: 25 iid: 1 pid: 480 pub: Wiley-Blackwell place: Malden, Massachusetts artinfo: ui: 183925938 179569985 183925938 183925938 10.1111/papr.13407 183925938 ppf: 1 ppct: 13 formats: fmt: – @attributes: type: T – @attributes: type: C – @attributes: type: P tig: atl: Low‐energy differential target multiplexed SCS derivative reduces pain and improves quality of life through 12 months in patients with chronic back and/or leg pain. aug: au: Peacock, Jeffery Provenzano, David Fishman, Michael Amirdelfan, Kasra Bromberg, Todd Schmidt, Todd White, Thomas Grewal, Prabhdeep Justiz, Rafael Calodney, Aaron El‐Naggar, Amr Shah, Binit Esposito, Michael Gatzinsky, Kliment Kallewaard, Jan Willem Poree, Lawrence Cleland, Andrew Rice, Calysta Theis, Erin Noel, Kate affil: Pain Management, Novant Health, Winston‐Salem North Carolina,, USA sug: subj: Back Pain Therapy Chronic Pain Therapy Spinal Cord Stimulation Evaluation Spinal Cord Stimulation Methods Quality of Life Treatment Outcomes Patient Safety Human United States Female Male Middle Age Aged Clinical Trials Prospective Studies Multicenter Studies Visual Analog Scaling Questionnaires Time Factors Pain Measurement Pain Management Patient Satisfaction Scales Data Analysis Software Confidence Intervals Descriptive Statistics Middle Aged: 45-64 years Aged: 65+ years Female Male ab: Introduction: Energy‐reducing spinal cord stimulation (SCS) approaches have the potential to impact patient experience with rechargeable and non‐rechargeable SCS devices through reducing device recharge time or enhancing device longevity. This prospective, multi‐center study evaluated the safety, effectiveness, and actual energy usage of differential target multiplexed (DTM) endurance therapy, a reduced energy DTM SCS derivative. Methods: Subjects who reported an overall pain visual analog score (VAS) of ≥6/10 cm and an Oswestry Disability Index score of 21–80 out of 100 at baseline with moderate to severe chronic, intractable back and/or leg pain were eligible. Evaluation visits occurred at 1, 3, 6, and 12 months post‐device activation. The primary objective was to characterize change in overall pain intensity, as measured by VAS, from baseline to 3‐month visit. Results: Fifty‐seven subjects enrolled at 12 US sites from November 2020 through June 2021, 35 were implanted with a rechargeable SCS device, and 27 completed the 12‐month visit. Subjects experienced a 50.4% mean reduction in overall pain from baseline at the 3‐month follow‐up that was sustained through 12 months. Additional outcomes including changes in overall, back, and leg pain intensity, quality of life, disability, therapy satisfaction, safety, and current battery usage are shown through 12‐month follow‐up. Conclusion: The use of DTM endurance SCS therapy in this study resulted in reductions in pain relief through 12 months, demonstrating that energy‐reducing stimulation patterns can provide clinical benefit. Clinically effective, reduced energy SCS derivatives have the potential to impact patient experience through either reduced recharge requirements or increased device longevity. pubtype: Academic Journal doctype: clinical trial research tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|